rolofylline has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Veryard, C | 1 |
| Robins, P | 1 |
2 other study(ies) available for rolofylline and Cardiovascular Diseases
| Article | Year |
|---|---|
American Heart Association - Scientific Sessions 2006. Developments in cardiovascular-related therapies.
Topics: Adenosine A2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Factor IXa; Factor XIa; Humans; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Staphylococcal Infections; Vancomycin; Xanthines | 2007 |
JPMorgan 25th annual healthcare conference. Pipelines from NovaCardia, Quark Biotech, Raven Biotechnologies and Serenex.
Topics: Adenosine A1 Receptor Antagonists; Biotechnology; Cardiovascular Diseases; Delivery of Health Care; Diuretics; Drug Industry; Humans; Membrane Transport Modulators; Mucositis; Thiazepines; Xanthines | 2007 |